- Dynavax Technologies (DVAX, Financial) plans a crucial proxy meeting on June 11, 2025.
- The firm reports a 267% total stockholder return over the past five years.
- Ongoing proxy battle with Deep Track Capital could impact Dynavax's strategic direction.
Dynavax Technologies (DVAX) has filed its definitive proxy materials with the SEC for its Annual Meeting on June 11, 2025. The company is urging stockholders to vote for its four director nominees using the GOLD proxy card. Over the past five years, Dynavax has achieved a remarkable 267% total stockholder return, highlighting its strong market performance, especially with its flagship hepatitis B vaccine, HEPLISAV-B®.
HEPLISAV-B® has seen significant net product revenue growth, from $36 million in 2020 to $268 million in 2024, capturing approximately 44% of the U.S. hepatitis B vaccine market. Dynavax expects further growth, projecting HEPLISAV-B® net product revenue of $305-325 million in 2025.
Dynavax's strategy includes a $200 million share repurchase program, with $128.8 million already executed in Q1 2025. The company continues to focus on the commercialization of HEPLISAV-B® and the development of its vaccine pipeline, expecting the U.S. hepatitis B vaccine market to reach $900 million by 2030.
The ongoing proxy battle with Deep Track Capital seeks to replace four independent directors and propose strategic changes, including increasing share repurchases to $400 million and focusing solely on HEPLISAV-B® commercialization. Dynavax contends that such proposals could be detrimental to long-term shareholder value.
